SARS-CoV-2 seroprevalence among the population of the Belgorod Region during the COVID-19 epidemic


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Objective. To study SARS-CoV-2 seroprevalence among the residents of the Belgorod Region. Subjects and methods. The investigation was conducted as part of Stage 1 assessing herd immunity to SARS-CoV-2 among the population of the Russian Federation, by using the unified procedure developed by the Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being with the participation of the Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology. Participants were selected by questionnaire survey and randomization. The results of surveying 2675 people were analyzed. Results. Community immunity in the region was 8.7% with maximum (14.5%) among children aged 1-6 years. There were no statistically significant differences between men and women in the level of seroprevalence. In COVID-19 convalescents, antibodies were detected in 23.1% of cases. In contacts with COVID-19 patients, the seroprevalence level increased by 1.6 times. In individuals who were asymptomatic and had a positive PCR test, specific antibodies were detected in 21.7% of cases. The infection was asymptomatic in 93.4% of seropositive individuals. Conclusion. The low proportion of seroprevalence among the population suggests that there may be a risk for reactivation of COVID-19.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Anna Popova

Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: depart@gsen.ru
Professor, MD Moscow, Russia

Elena Ezhlova

Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: ezhlova_eb@gsen.ru
Cand. Med. Sci. Moscow, Russia

Albina Melnikova

Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: melnikova_aa@gsen.ru
Cand. Med. Sci., Epidemiological Surveillance Directorate Moscow, Russia

Elena Oglezneva

Directorate for the Belgorod Region, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: orgotd@31rospotrebnadzor.ru
Directorate for the Belgorod Region Belgorod, Russia

Aleksandr Krasnoperov

Center for Hygiene and Epidemiology in the Belgorod Region

Email: orgotdel@31fbuz.ru
Belgorod, Russia

Lyudmila Lyalina

Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology. Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Professor, MD Saint Petersburg, Russia

Vyacheslav Smirnov

Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology. Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: vssmi@mail.ru
Professor, MD Saint Petersburg, Russia

Andrey Demin

Center for Hygiene and Epidemiology in the Belgorod Region

Email: demin@31fbuz.ru
Belgorod, Russia

Zh. Kobrinets

Center for Hygiene and Epidemiology in the Belgorod Region

Email: orgotdel@31fbuz.ru
Zhanna V. Belgorod, Russia

Aleksandra Cherskova

Center for Hygiene and Epidemiology in the Belgorod Region

Email: sgm@31fbuz.ru
Belgorod, Russia

Vsevolod Zhidkov

Center for Hygiene and Epidemiology in the Belgorod Region

Email: orgotdel@31fbuz.ru
Belgorod, Russia

Daria Velitchenko

Center for Hygiene and Epidemiology in the Belgorod Region

Email: orgotdel@31fbuz.ru
Belgorod, Russia

Tatiana Arbuzova

Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology. Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: arbuzowa95@yandex.ru
Saint Petersburg, Russia

Valeria Lomonosova

Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology. Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: valeriyanagorskaya94@yandex.ru
Saint Petersburg, Russia

Areg Totoyan

Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology. Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: pasteur@pasteurorg.ru
Professor, Academician of the Russian Academy Saint Petersburg, Russia

Әдебиет тізімі

  1. Wu F., Zhao S., Yu B., Chen Y.M., Wang W., Song Z.G. et al. A new coronavirus associated with human respiratory disease in China. Nature 2020; 579(7798): 265-9. doi: 10.1038/s41586-020-2008-3
  2. Nicholls J., Dong X.P., Jiang G., Peiris M. SARS: clinical virology and pathogenesis. Respirology. 2003; 8(Suppl 1): S6-8. doi: 10.1046/j.1440-1843.2003.00517.x
  3. Porcheddu R., Serra C., Kelvin D., Kelvin N., Rubino S. Similarity in Case Fatality Rates (CFR) of COVID-19/ SARS-COV-2 in Italy and China. J. Infect. Dev. Ctries. 2020; 14(2): 125-8. doi: 10.3855/jidc.12600
  4. Wu D., Wu T., Liu Q., Yang Z. The SARS-CoV-2 outbreak: What we know. Int. J. Infect. Dis. 2020; 94: 44-8. doi: 10.1016/j.ijid.2020.03.004
  5. Kamel Boulos M.N., Geraghty E.M. Geographical tracking and mapping of coronavirus disease COVID-19/severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic and associated events around the world: how 21st century GIS technologies are supporting the global fight against outbreaks and epidemics. Int. J. Health Geogr. 2020; 19(1): 8. doi: 10.1186/s12942-020-00202-8
  6. Liu R., Han H., Liu F., Lv Z., Wu K., Liu Y. et al. Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020. Clin. Chim. Acta. 2020; 505: 172-5. doi: 10.1016/j.cca.2020.03.009
  7. WHO Director-General’s speech at press briefing on coronavirus infection 2019-nCoV, 11 February. https:// www.who.int/ru/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on- 11-february-2 020
  8. Clemente-Suärez V.J., Hormeno-Holgado A., Jimdnez M., Benitez-Agudelo J.C., Navarro-Jimdnez E., Perez-Palencia N. et al. Dynamics of Population Immunity Due to the Herd Effect in the COVID-19 Pandemic. Vaccines (Basel). 2020; 8(2): 236. doi: 10.3390/vaccines8020236
  9. Laxminarayan R., John T.J. Is Gradual and Controlled Approach to Herd Protection a Valid Strategy to Curb the COVID-19 Pandemic? Indian Pediatr. 2020; 57(6): 505-7. doi: 10.1007/s13312-020-1844-4
  10. Kochi A.N., Tagliari A.P., Forleo G.B., Fassini G.M., Tondo C. Cardiac and arrhythmic complications in patients with COVID-19. J. Cardiovasc. Electrophysiol. 2020; 31(5): 1003-8. doi: 10.1111/jce.14479
  11. Juan J., Gil M.M., Rong Z., Zhang Y., Yang H., Poon L.C. Effect of coronavirus disease 2019 (COVID-19) on maternal, perinatal and neonatal outcome: systematic review. Ultrasound Obstet. Gynecol. 2020; 56(1): 15-27. doi: 10.1002/uog.22088
  12. Попова А.Ю., Ежлова Е.Б., Мельникова А.А., Башкетова Н.С., Фридман Р.К., Лялина Л.В., Смирнов В.С., Чхинджерия И.Г., Гречанинова Т.А., Агапов К.А., Арсентьева Н.А., Баженова Н.А., Бацунов О.К., Данилова Е.М., Зуева Е.В., Комкова Д.В., Кузнецова Р.Н., Любимова Н.Е., Маркова А.Н., Хамитова И.В., Ветров В.В., Миличкина А.М., Дедков В.Г., Тотолян А.А. Популяционный иммунитет к вирусу SARS-COV-2 среди населения Санкт-Петербурга в активную фазу эпидемии COVID-19. Проблемы особо опасных инфек ций 2020; (3): 124-30. doi: 10.21055/0370-1069-2020-3124-130
  13. Newcombe R.G. Two-Sided Confidence Intervals for the Single Proportion: Comparison of Seven Methods. Statistics in Medicine 1998; 17: 857-87. doi: 10.1002/(sici) 1097-0258(19980430)17:8<857::aid-sim777>3.0.co;2-e
  14. Hou H., Wang T., Zhang B., Luo Y., Mao L., Wang F. et al. Detection of IgM and IgG antibodies in patients with coronavirus disease 2019. Clin. Transl. Immunology 2020; 9(5): e01136. doi: 10.1002/cti2.1136
  15. Vabret N., Britton G.J., Gruber C., Hegd S., Kim J., Kuksin M. et al. The Sinai Immunology Review Project. Immunology of COVID-19: cur-rent state of the science. Cell Press, 2020. DOI: https://doi.org/10.10167j.immuni.2020.05.002
  16. Chang D., Mo G., Yuan X., Tao Y., Peng X., Wang F.-S. et al. Time Kinetics of Viral Clearance and Resolution of Symptoms in Novel Coronavirus Infection. Am. J. Respir. Crit. Care Med. 2020; 201(9): 1150-2. doi: 10.1164/rccm.202003-0524LE
  17. Kronbichler A., Kresse D., Yoon S., Lee K.H., Effenberger M., Shin J.I. Asymptomatic patients as a source of COVID-19 infections: A systematic review and meta-analysis. Int. J. Infect. Dis. 2020; 98: 180-6. doi: 10.1016/j. ijid.2020.06.052. 15
  18. Попова А. Ю., Ежлова Е. Б., Мельникова А. А., Историк О. А., Мосевич О. С., Лялина Л. В. и др. Опыт оценки популяционого иммунитета к SARS-COV-2 среди населения Ленинградской области в период эпидемии COVID-19. Проблемы особо опасных инфекций 2020; (3): 114-23. doi: 10.21055/0370-1069-2020-3-114-123
  19. Vlasova A.N., Zhang X., Hasoksuz M., Nagesha H.S., Haynes L.M., Y. Fang et al. Two-Way Antigenic CrossReactivity between Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Group 1 Animal CoVs Is Mediated through an Antigenic Site in the N-Terminal Region of the SARS-CoV Nucleoprotein. J. Virol. 2007; 81(240022): 13365-77. doi: 10.1128/JVI.01169-07
  20. Lynch K.L., Whitman J.D., Lacanienta N.P., Beckerdite E.W., Kastner S.A., Shy B.R. et al. Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity. Clin. Infect. Dis. 2020; 14: 979. doi: 10.1093/ cid/ciaa979
  21. Cai J., Sun W., Huang J., Gamber M., Wu J., He G. Indirect Virus Transmission in Cluster of COVID-19 Cases, Wenzhou, China, 2020. Emerg. Infect. Dis. 2020; 26(6): 1343-5. doi: 10.3201/eid2606.200412

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2021

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>